newsfilter
← Latest News
GlobeNewswire·

Keros Therapeutics Reports Third Quarter 2025 Financial Results

LEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel